Ann: Share purchase plan (SPP) - closing date extended, page-10

First 10 Last

Share
Profile

Follow
Steini

12,608 Posts.

3834

06/06/23

15:34

Post #: 68156695
Share

Originally posted by dalts66: ↑

Interesting you talk of IMU below 10c. I still hold a truck load of IMU, but looking at market caps, CHM still provides more potential upside than IMU, even with it below 10c.

I can see IMU bouncing 3 bags to be at fair value from 10c, and CHM bouncing 10 bags to fair value. More risk with CHM, and with this risk the greater potential to reward (or loss),

The phase 1b expansion trial is Interesting. We know lower doses have lead to 75% of patents (low cohort number, but this is still significant) and an extension of life. even at low (below hypothetical dose) dose. The 4th cohort is believed to be closer to the goldilocks number of cells, and its underway now. But the expansion trial is now also underway. They must have good data to start this prior to the 4th cohort ending. The expansion trial will be the building block for the fast track registration trial.

Have a look at early approvals for the first CarTs. There is presidents of approvals after phase 1b for treatment of cancers with no SOC. And these drugs had 75% adverse event rates. CHM's drug has had no dose limiting events, so safety is good.

The patient cohort in the trials so far, were selected as they had a particular biomarker that the CHM drug targets. These patients has SOC fail them prior to entering the trial. 75% of them achieved stable disease at low drug dose rates. This is unheard of for GBM. This also shows that the CHM CarT is showing efficacy against solid tumour cancer. This is also unheard of.

The hospital where the phase 1a trial was being conducted, gave approval for the expansion trial. They wont do that if the drug isnt working. They are a major cancer research institution and wont put there reputation at risk.

The market cap is sub $17 million. Two drugs are hitting arms right now. One of those trials is paid for by another party. Another drug is ready to hit arms.

At this market cap any dilution that will happen due to capital raising still allows for many multiples of growth. And with a potential registration trial in the medium future dilution may be less than we think.

It would appear that the current SPP is to get us past the end of the year. Data from cohort 4 and expansion trial should coincide with this. So still some pain ahead, but very interesting medium to long term.

Expand

I agree with you on all points but the ASX market is the problem. As IMU's CF33 potential and results achieved so far have been ignored how in the world can get CHM any attention. The only way currently is an offer of any kind by big pharma. Look at IMU 10.5c sell line, if there was an accumulator it would have been swallowed, but there is Zero interest. Same here. IMO, if there is a turnaround, then probably first at IMU.

Market only understands $ and rock chip sample grades and may jump on the 2 letters AI and the element of H2, but nothing else.

GLTA

CHM Price at posting: 3.9¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

EXR

Essential Energy conference: Elixir talks up unlocking QLD's Taroom Trough

Essential Energy conference: Streamlining approvals key to the green energy transition

HVN

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

BPM

BPM Minerals hits high-grade gold at the Claw Project WA; shares jump 86%

88E

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

There are more pages in this discussion • 11 more messages in this thread...

First 10 Last

Add CHM (ASX) to my watchlist

(20min delay)
Last 1.5¢		Change 0.000(0.00%)		Mkt cap ! $13.40M

Open	High	Low	Value	Volume
1.6¢	1.6¢	1.5¢	$22.18K	1.435M

Buyers (Bids)

No.	Vol.	Price($)
15	2023849	1.5¢

Sellers (Offers)

Price($)	Vol.	No.
1.7¢	872843	3

View Market Depth

No.	Vol.	Price($)
15	2023849	0.015
7	998928	0.014
4	1266666	0.013
5	313515	0.012
3	385859	0.011

Price($)	Vol.	No.
0.017	872843	3
0.018	1200000	4
0.019	1693686	5
0.020	204343	6
0.021	140000	1

Last trade - 16.10pm 18/09/2024 (20 minute delay)

CHM (ASX) Chart

Ann: Share purchase plan (SPP) - closing date extended, page-10

Essential Energy conference: Elixir talks up unlocking QLD's Taroom Trough

Essential Energy conference: Streamlining approvals key to the green energy transition

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

BPM Minerals hits high-grade gold at the Claw Project WA; shares jump 86%

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Share purchase plan (SPP) - closing date extended, page-10

Top Stories

Essential Energy conference: Elixir talks up unlocking QLD's Taroom Trough

Essential Energy conference: Streamlining approvals key to the green energy transition

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

BPM Minerals hits high-grade gold at the Claw Project WA; shares jump 86%

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News